4.4 Article

Interleukin-21 up-regulates interleukin-21R expression and interferon gamma production by CD8+ cells in SHIV-infected macaques

Journal

EXPERIMENTAL BIOLOGY AND MEDICINE
Volume 238, Issue 4, Pages 400-410

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/1535370213477978

Keywords

Simian/human immunodeficiency virus; interleukin-21; T-cell; interferon-gamma; IL-21 receptor; STAT3

Funding

  1. National Science and Technology Major projects of Infectious Disease [2012 2 x 10004-501, 2012 2 x 10001-007, 2012 2 x 10001-006]

Ask authors/readers for more resources

Interleukin-21 (IL-21) is produced primarily by CD4+T cells and regulates immunity against human/simian immunodeficiency virus (HIV/SIV) infection. Activated CD8+ cells and their secreted interferon-gamma (IFN-gamma) are crucial for the control of acute HIV/SIV infection. However, whether IL-21 can regulate IFN-gamma production by CD8+ cells remains controversial. Rhesus macaques (RMs, n = 8) were infected with SHIV and the levels of plasma IL-21, IFN-gamma and the frequency of peripheral blood activated T cells were measured longitudinally. Following infection with SHIV, the levels of plasma IL-21 and IFN-gamma increased, peaked at 17 days postinfection and declined later. Furthermore, IL-21 induced IL-21 receptor (IL-21R) and IFN-gamma, perforin, but not granmyze B, expression in CD8+ cells from four selected SHIV-infected RMs. The regulatory effect of IL-21 on CD8+ cell function appeared to be associated with increased levels of STAT3, but not STAT5, phosphorylation in CD8+ cells from SHIV-infected RMs. In parallel, treatment with soluble IL-21R/Fc, an inhibitor of IL-21-induced activation of JAK1/3 and STAT3, abrogated IL-21-induced STAT3 activation and IFN-gamma production in CD8+ cells from SHIV-infected RMs in vitro. Our data indicated that IL-21 was a positive regulator of IFN-gamma secreting CD8+ cells and increased the STAT3 phosphorylation, regulating T-cell immunity against acute SHIV infection in RMs. Our findings may provide a new basis for the development of immunotherapies for the control of SHIV/HIV infection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available